Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Cannabis

Canntab Therapeutics names Richard Goldstein as interim CEO, replacing Larry Latowsky

He replaces outgoing CEO Larry Latowsky who stepped down to pursue other opportunities

Canntab Therapeutics Ltd (CSE:PILL, OTCQB:CTABF) said it has appointed Richard Goldstein, currently the company's chief financial officer (CFO), as its interim chief executive officer (CEO), effective July 31 this year.

He replaces outgoing CEO Larry Latowsky who stepped down to pursue other opportunities.

Latowsky will continue to serve as an advisor to the board and oversee the direction and development of business with First Nations communities across Canada per agreements previously announced, said Canntab.

READ: Canntab Therapeutics appoints Hamish Sutherland as strategic business consultant

The board of directors has begun a formal search for a permanent CEO, it added.

Canntab is a Canadian phytopharmaceutical company focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations.

Contact the writer at giles@proactiveinvestors.com

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK